Tyrosine phosphatase PRL-1 is one of the immediate-early genes up-regulated during liver regeneration and is apparently involved in cell proliferation. Previously, we have demonstrated that
halofuginone, an inhibitor of
collagen type I synthesis, prevents
liver fibrosis and improves cirrhotic liver regeneration. In this study, we evaluated the effect of
halofuginone on PRL-1 expression, its cellular localization in vitro and during liver regeneration, and
fibrosis progression in vivo. In culture,
halofuginone increased PRL-1 expression in primary rat hepatocytes and in
hepatocellular carcinoma (HCC) cell lines, the former being more sensitive to
halofuginone. The
halofuginone-dependent increase in PRL-1 gene expression was correlated with an increase in the
transcription factor early growth response-1 (Egr-1) and inversely correlated with the inhibition of cell proliferation.
Halofuginone arrested HepG2 and Huh7 cell lines at the G1 phase, whereas Hep3B cells were arrested at G2/M, probably because of a reduction in the synthesis of
cyclins D1 and B1 in all HCC cells and increased
cyclin A in Hep3B cells.
Halofuginone also affected the PRL-1 sub-cellular localization that was cell-cycle-dependent. In addition,
halofuginone augmented PRL-1 expression in the remnant liver after partial
hepatectomy and in chemically induced
fibrosis in rats; this was accompanied by increased expression of
insulin-like growth factor binding protein 1 (IGFBP-1), another immediate-early gene of regeneration. The regulation of the expression of the early genes of regeneration such as PRL-1 and
IGFBP-1 is thus part of the mode of action of
halofuginone and results in the prevention of
liver fibrosis and improved cirrhotic liver regeneration.